<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802395</url>
  </required_header>
  <id_info>
    <org_study_id>RAI 19-1004</org_study_id>
    <nct_id>NCT04802395</nct_id>
  </id_info>
  <brief_title>Real World Evidence Clinical Utility Study of KidneyIntelX</brief_title>
  <official_title>Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renalytix AI, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Renalytix AI, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part&#xD;
      of the current standard of care on the management of patients seen in the primary care&#xD;
      physician's office at Mount Sinai.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Telemedicine</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion (target: 30%) scheduled or completed telemedicine instead of face-to-face visits; this will also include a change in frequency of telemedicine visits based on KidneyIntelX risk profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Referrals</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion (target: 20%) of patients referred to a dietician, diabetologist, or nephrologist.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Statins and or ACEi/ARB</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients treated with statins and or angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients to receive information and or advice on their individualized target of HbA1c.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SGLT2/ GLP1</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion (target: 20% increase) of patients treated with SGLT2 inhibitors or GLP1 agonists.</description>
  </primary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Diabetic Kidney Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>KidneyIntelX</intervention_name>
    <description>KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Type 2 diabetes and existing chronic kidney disease stages 1-3.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease&#xD;
             (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patents without the appropriate characteristics as identified in the KidneyIntelX&#xD;
             intended use population.&#xD;
&#xD;
          -  Patients with eGFR &lt;30 or ≥ 60 ml/min/1.73m2 without albuminuria.&#xD;
&#xD;
          -  Patients with ESRD or on renal recovery treatments at time of enrollment.&#xD;
&#xD;
          -  Patients who are pregnant at the time of enrollment.&#xD;
&#xD;
          -  Patients who are currently hospitalized.&#xD;
&#xD;
          -  Patients without minimum 6 month pre-baseline KidneyIntelX medical history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger Tun</last_name>
    <phone>646-397-3970</phone>
    <phone_ext>106</phone_ext>
    <email>rtun@renalytixai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

